Baird analyst Eric Coldwell upgrades Medpace Hldgs (NASDAQ:MEDP) from Neutral to Outperform and raises the price target from $270 to $289.
Baird Upgrades Medpace Hldgs to Outperform, Raises Price Target to $289
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.